Remove Clinical Trials Remove Containment Remove Drugs Remove FDA Approval
article thumbnail

Wainua (Eplontersen) Now FDA-Approved for Rare Disease ATTRv-PN

XTalks

Wainua is the only FDA-approved drug for the treatment of ATTRv-PN that can be self-administered via an auto-injector. Approval of Wainua represents a meaningful advancement in treatment, one that gives those who are living with transthyretin-mediated amyloid polyneuropathy help managing the disease,” said Michael J.

article thumbnail

Filsuvez Topical Gel Gets FDA Approval for Epidermolysis Bullosa

XTalks

Chiesi Global Rare Diseases, a specialized division within the Chiesi Group dedicated to pioneering therapies for individuals affected by rare diseases, has received approval from the US Food and Drug Administration (FDA) for Filsuvez (birch triterpenes) topical gel. Specifically, 41.3 percent observed in the control gel arm.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US FDA approves Takeda’s HyQvia to treat PI in children

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Takeda ’s supplemental Biologics Licence Application (sBLA) to expand the use of its HyQvia subcutaneous immune globulin (ScIG) for the treatment of primary immunodeficiency (PI) in children aged between two and 16 years. This was a primary endpoint of the trial.

article thumbnail

Izervay Becomes Second FDA-Approved Drug for Geographic Atrophy

XTalks

Iveric Bio, a company of Astellas, has secured recent approval from the US Food and Drug Administration (FDA) for its innovative drug, Izervay (avacincaptad pegol intravitreal solution). Izervay contains avacincaptad pegol sodium, an effective complement C5 inhibitor. How Does Izervay Work?

article thumbnail

STAT+: Mirati wins FDA approval for KRAS-blocking lung cancer drug, but blockbuster sales hopes have dimmed

STAT News

The Food and Drug Administration on Monday approved a second KRAS-blocking treatment for advanced lung cancer. However, hopes the drug might reach a large swath of patients — and grow into a commercial blockbuster for its maker Mirati Therapeutics — have dimmed in the wake of underwhelming clinical trial results.

article thumbnail

Adzynma Wins FDA Approval as First Treatment for Ultra-Rare Blood Clotting Disorder cTTP

XTalks

The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals’ Adzynma, the first recombinant protein product for prophylactic (preventive) or on‑demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), an ultra-rare blood clotting disorder.

article thumbnail

Elrexfio Becomes Pfizer’s First Approved Multiple Myeloma Drug

XTalks

After Johnson & Johnson’s US Food and Drug Administration (FDA) approval last week for its second multiple myeloma bispecific, Talvey (talquetamab), Pfizer received an FDA nod for its B-cell maturation antigen (BCMA)-directed therapy Elrexfio (elranatamab) in the same indication.